WO2002040507A3 - Nouveaux composes pour des applications a la radioimmunoscintigraphie et/ou a la radioimmunotherapie des cancers - Google Patents

Nouveaux composes pour des applications a la radioimmunoscintigraphie et/ou a la radioimmunotherapie des cancers Download PDF

Info

Publication number
WO2002040507A3
WO2002040507A3 PCT/FR2001/003616 FR0103616W WO0240507A3 WO 2002040507 A3 WO2002040507 A3 WO 2002040507A3 FR 0103616 W FR0103616 W FR 0103616W WO 0240507 A3 WO0240507 A3 WO 0240507A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
radioimmunoscintigraphy
radioimmunotherapy
radionuclide
represent
Prior art date
Application number
PCT/FR2001/003616
Other languages
English (en)
Other versions
WO2002040507A2 (fr
Inventor
Laurence Morandeau
Patricia Remaud
Alain Faivre-Chauvet
Jean-Francois Gestin
Original Assignee
Inst Nat Sante Rech Med
Laurence Morandeau
Patricia Remaud
Alain Faivre-Chauvet
Jean-Francois Gestin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Laurence Morandeau, Patricia Remaud, Alain Faivre-Chauvet, Jean-Francois Gestin filed Critical Inst Nat Sante Rech Med
Publication of WO2002040507A2 publication Critical patent/WO2002040507A2/fr
Publication of WO2002040507A3 publication Critical patent/WO2002040507A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D259/00—Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention a pour objet des composés de formule générale (I), dans laquelle U représente un agent chélatant capable de fixer au moins un radionucléide, B représente un groupe de formule (II), Y représente un chaînon métabolisable dans le foie ou dans les reins, R représente NH, NHCS, NHCOCH2, ou un groupe NHCO-W-CO, A représente un cycle, aromatique ou non, le cas échéant substitué, X représente N ou CH, V1 et V2, représentent CO, NH, NH-CO, ou CO-NH, L1 et L2 représentent un motif, notamment un enchaînement hétéropeptidique, ou peptidique, capable de reconnaître spécifiquement des anticorps déterminés. L'invention concerne également l'utilisation d'un composé susmentionné ou d'un complexe entre ce composé et un radionucléide, pour la préparation d'un médicament pour la radiothérapie, le diagnostic de pathologies telles que les cancers, le traitement des déchets radioactifs, ou le dosage ou la purification de radionucléides ou de métaux.
PCT/FR2001/003616 2000-11-16 2001-11-16 Nouveaux composes pour des applications a la radioimmunoscintigraphie et/ou a la radioimmunotherapie des cancers WO2002040507A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/14797 2000-11-16
FR0014797A FR2816620B1 (fr) 2000-11-16 2000-11-16 Nouveaux composes pour des applications a la radioimmunoscintingraphie et/ou a la radioimmunotherapie des cancers

Publications (2)

Publication Number Publication Date
WO2002040507A2 WO2002040507A2 (fr) 2002-05-23
WO2002040507A3 true WO2002040507A3 (fr) 2002-07-11

Family

ID=8856548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003616 WO2002040507A2 (fr) 2000-11-16 2001-11-16 Nouveaux composes pour des applications a la radioimmunoscintigraphie et/ou a la radioimmunotherapie des cancers

Country Status (2)

Country Link
FR (1) FR2816620B1 (fr)
WO (1) WO2002040507A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
CN114409578B (zh) * 2022-01-28 2022-10-14 安源基因科技(上海)有限公司 一种多元适体分子的制备方法
CN114441749B (zh) * 2022-01-28 2022-09-30 安源基因科技(上海)有限公司 一种新型多元适体分子在磁珠免疫化学发光afp中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2652004A1 (fr) * 1989-09-21 1991-03-22 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
FR2697255A1 (fr) * 1992-10-27 1994-04-29 Immunotech Partners Nouveaux dérivés bihaptènes liant le technétium, application au diagnostic et à la thérapeutique, kits et réactifs immunologiques les mettant en Óoeuvre.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2652004A1 (fr) * 1989-09-21 1991-03-22 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
EP0419387A1 (fr) * 1989-09-21 1991-03-27 IMMUNOTECH PARTNERS: Société en Commandite par Actions dite Nouveaux dérivés hydrophiles, application au diagnostic et à la thérapeutique, kits diagnostiques ou thérapeutiques et réactifs immunologiques
FR2697255A1 (fr) * 1992-10-27 1994-04-29 Immunotech Partners Nouveaux dérivés bihaptènes liant le technétium, application au diagnostic et à la thérapeutique, kits et réactifs immunologiques les mettant en Óoeuvre.
EP0595743A1 (fr) * 1992-10-27 1994-05-04 IMMUNOTECH PARTNERS:Société Anonyme dite Dérivés bi-haptènes liant le technétium ou le rhénium procédé de préparation, application au diagnostic et à la thérapeutique, kits et réactifs immunologiques les renfermant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E JANEVIK-IVANOVSKA ET AL.: "Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy", BIOCONJUGATE CHEMISTRY, vol. 8, 1997, WASHINGTON US, pages 526 - 533, XP002145188 *
J F GESTIN ET AL.: "Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies", JOURNAL OF NUCLEAR MEDICINE., vol. 42, no. 1, January 2001 (2001-01-01), SOCIETY OF NUCLEAR MEDICINE. NEW YORK., US, pages 146 - 153, XP002178931, ISSN: 0161-5505 *

Also Published As

Publication number Publication date
WO2002040507A2 (fr) 2002-05-23
FR2816620B1 (fr) 2003-02-21
FR2816620A1 (fr) 2002-05-17

Similar Documents

Publication Publication Date Title
DK0417870T3 (da) Chelatdannere til kompleksbinding af radioaktive isotoper, metalkomplekser deraf samt anvendelsen deraf til diagnostik og terapi
WO2004065407A3 (fr) Composes de peptide liberant la gastrine
WO1995033497B1 (fr) Agents chelateurs metalliques a base de thiol, diamide et monoamine
ES2175162T3 (es) Marcaje con radionuclidos de vitamina b12 y coenzimas de la misma.
US7163935B2 (en) Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
PT1572246E (pt) Novas composições de partículas magnéticas cobertas com derivados gem-bisfosfonatos
DE69526515T2 (de) Tc oder re radiomarkierte somastostatin analoge
HK1064585A1 (en) Improved chelator conjugates.
WO2005053752A3 (fr) Nouveaux agents d'imagerie
WO2002040507A3 (fr) Nouveaux composes pour des applications a la radioimmunoscintigraphie et/ou a la radioimmunotherapie des cancers
DE69529988D1 (de) Technetium-99m markierte bildformungsmittel
HU9502868D0 (en) Chelating agents of the type xn1s1o1 for radioactive isotopes, metal complexes thereof, and their use in diagnosis and therapy
WO1998014220A3 (fr) PEPTIDES CYCLIQUES CONTENANT DES AGENTS CHELATANTS ET MARQUES AU TECHNETIUM 99 m
WO2001051095A3 (fr) Derives paramagnetiques de type dota, agents pharmaceutiques les contenant, procedes permettant de les preparer et leur utilisation pour l'imagerie par resonance magnetique de necroses et de l'infarctus
WO1997010853A3 (fr) Agents de formation de chelates de nicotinamide bifonctionnels du type n2s2 pour isotopes radioactifs
SI1603598T1 (sl) Radiooznačeni konjugati na osnovi substance P innjihove uporabe
WO2002040060A3 (fr) Conjugues d'antioxydants et de ligands de chelation metallique destines a des applications diagnostiques et therapeutiques
DE69723242D1 (de) Ternäre radiopharmazeutische komplexe
EP0431146A4 (en) Radionuclide metal chelates for the radiolabeling of proteins
NO961743L (no) N-alkyl-peptid-chelatdannere, deres metallkomplekser med radionuklider, fremgangsmåte ved deres fremstilling og radiofarmasöytiske sammensetninger inneholdende disse forbindelser
CA2190727A1 (fr) Ligands d'atomes donneurs d'azote et de soufre pontes et substitues par amines aromatiques, utilises en imagerie
DE60024891D1 (de) Makrocyclische Chelatbildner für Metallopharmazeutika
ATE190053T1 (de) Aromatische aminsubstituierte liganden mit verbrückten stickstoff-und schwefeldonatoratomen für bildformung
TW291440B (en) Gallium dimercaptosuccinate as novel tumor imaging agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP